Spots Global Cancer Trial Database for Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase 1 Study of the Effect of Ketoconazole on the PK of Multiple Doses of Cediranib in Patients With Solid Tumours
Official Title: A Phase I, Open Label, Non-Randomised Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Multiple Oral Doses of Cediranib (AZD2171, RECENTINÔ), in Patients With Advanced Solid Tumours
Study ID: NCT00750425
Conditions
Interventions
Study Description
Brief Summary: Phase I, open study to assess the effect of ketoconazole, a marketed drug, on the way the body handles the experimental drug cediranib, in patients with advanced cancer.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Hamilton, , Canada
Research Site, Toronto, , Canada
Research Site, Vancouver, , Canada
Research Site, Herlev, , Denmark
Research Site, Kobenhavn, , Denmark
Contact Details
Name: Jane Roberston
Affiliation: AstraZeneca Aderley Park
Role: STUDY_DIRECTOR
Name: Dr U Lassen, MD PhD
Affiliation: The Finsen Center, Copenhagen, Denmark
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
